HALO Halozyme Therapeutics, Inc.

12.61
+0.05  (0.4%)
Previous Close 12.56
Open 12.49
Price To book 0.00
Market Cap 1.62B
Shares 128,154,000
Volume 1,008,624
Short Ratio 8.07
Av. Daily Volume 1,864,290

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA June 26, 2017.
Subcutaneous rituximab
Various blood cancers
Phase 1/2 trials to be initiated in 2017.
Tecentriq and PEGPH20
Pancreatic and gastric cancers
Phase 1/2 initiated July 2016
Eribulin In Combination With PEGPH20
High-Hyaluronan (HA) HER2-negative breast cancer
Approved Sept 12 2014
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 dosing initiated March 2016. Phase 2 data released January 5, 2017.
PEGPH20
Pancreatic cancer
Phase 1b enrolment resumed July 2016 under revised protocol
PEGPH20 in combination with KEYTRUDA
Non-small cell lung cancer (NSCLC)
Phase 2 topline data released 1Q 2014
HTI-501
Celluoite

Latest News

  1. MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20
  2. Why Halozyme Therapeutics, Inc. Jumped 15.6% in January
  3. Halozyme To Host Fourth Quarter 2016 Financial Results Conference Call
  4. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 27, 2017
  5. 5 Small-Cap Biotech Stocks to Buy in February
  6. ETFs with exposure to Halozyme Therapeutics, Inc. : January 17, 2017
  7. Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : January 16, 2017
  8. Halozyme Estimates 2017 Revenue of $115M to $130M
  9. Why trader is selling Halozyme calls
  10. Here's Why Halozyme Therapeutics Fell as Much as 11.1% Today
  11. HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  12. Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
  13. HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
  14. Halozyme Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference
  15. Can the Rally in Halozyme (HALO) Shares Continue?
  16. Biotech Industry Off to a Strong Start in 2017 Latest Reports on Halozyme Therapeutics and Geron
  17. ETFs with exposure to Halozyme Therapeutics, Inc. : January 6, 2017
  18. Why Halozyme Therapeutics, Inc Fell 40.6% in 2016
  19. Company News for January 06, 2017
  20. Halozyme Pancreatic Cancer Drug Succeeds in Trial